Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
REPL Replimune Group Inc
- Stocks
- Healthcare
- NASDAQ: REPL
Price (delayed)
$8.07
Market cap
$621.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.07
Enterprise value
$523.61M
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary
Highlights
The company's equity rose by 26% QoQ and by 14% YoY
The company's EPS rose by 2.8% YoY
Replimune Group's quick ratio has increased by 13% from the previous quarter but it has decreased by 8% YoY
The net income has contracted by 9% YoY and by 7% from the previous quarter
Key stats
What are the main financial stats of REPL
Market
Valuations
Earnings
Shares outstanding
77.01M
Market cap
$621.51M
Enterprise value
$523.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.14
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$241.06M
Net income
-$228.24M
EBIT
-$219.87M
EBITDA
-$216.52M
Free cash flow
-$191.98M
Per share
Balance sheet
Liquidity
EPS
-$3.07
EPS diluted
-$3.07
Free cash flow per share
-$2.3
Book value per share
$7.05
Revenue per share
$0
TBVPS
$7.23
Total assets
$603.63M
Total liabilities
$121.25M
Debt
$76.04M
Equity
$482.37M
Working capital
$499.69M
Debt to equity
0.16
Current ratio
11.43
Quick ratio
11.3
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43%
Return on equity
-54.8%
Return on invested capital
-50.5%
Return on capital employed
-39.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
REPL stock price
How has the Replimune Group stock price performed over time
Intraday
3.86%
1 week
-19.38%
1 month
10.4%
1 year
19.91%
YTD
-33.36%
QTD
-17.23%
Financial performance
How have Replimune Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$241.06M
Net income
-$228.24M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 9% YoY and by 7% from the previous quarter
The operating income has declined by 5% year-on-year and by 4.1% since the previous quarter
Price vs fundamentals
How does REPL's price correlate with its fundamentals
Growth
What is Replimune Group's growth rate over time
Valuation
What is Replimune Group stock price valuation
P/E
N/A
P/B
1.14
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 2.8% YoY
REPL's price to book (P/B) is 54% lower than its 5-year quarterly average of 2.4 and 31% lower than its last 4 quarters average of 1.6
The company's equity rose by 26% QoQ and by 14% YoY
Efficiency
How efficient is Replimune Group business performance
REPL's ROE is down by 28% YoY and by 3.2% QoQ
Replimune Group's return on invested capital has decreased by 26% YoY and by 8% QoQ
Replimune Group's return on assets has decreased by 20% YoY and by 3.6% QoQ
Dividends
What is REPL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for REPL.
Financial health
How did Replimune Group financials performed over time
The total assets is up by 21% from the previous quarter and by 13% YoY
Replimune Group's quick ratio has increased by 13% from the previous quarter but it has decreased by 8% YoY
Replimune Group's debt is 84% less than its equity
The company's equity rose by 26% QoQ and by 14% YoY
The debt to equity has declined by 20% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.